Binance
Exchange №1 for Trading Cryptocurrencies
Start Now
BTC $ 3,974.3 -0.17%
ETH $ 147.44 0.01%
MARKET CAP $ 134 bln -0.46%
ICOs 5,302
Translate this page
0

Stem Cell

ICO Ended
4,234 Views
At SCI, we are devoted to the international research, development, and implementation of stem cell therapy. We are also expanding our network with professionals, labs, clinics, hospitals, and nonprofit organizations. Our ultimate goal at SCI is to connect people who need treatment with the right dedicated solutions and professionals for their unique needs. At SCI, we believe such connections should be convenient and at your fingertips, just as so many other services are in modern society. We imagine a world where each and every person, no matter where they come from, will be able to connect with a Stem Cel Specialist instantly through our Stem Cell Innovations application (SCI Application), and in the same connection be able to decide when and how much confidential information to share with professionals.
8.8
TOTAL SCORE
8.1
ICO PROFILE

(weight: 45%)

9
SOCIAL ACTIVITY

(weight: 35%)

10
TEAM PROOF

(weight: 20%)

Get widget
General
Website: Visit
White paper: Read
Pre-sale Time: 17 Sept 2018 - 09 Oct 2018
ICO Time: 21 Nov 2018 - 17 Jan 2019
Whitelist/KYC: KYC
Country: Gibraltar
Token info
Ticker: SCI
Platform: Ethereum
Token Type: ERC20
Available for sale: 800,000,000 SCI
Financial
ICO Price: 1 SCI = 0.15 USD
Accepting: BTC, ETH, LTC, Fiat
Soft cap: 3,000,000 USD
Hard cap: 36,000,000 USD
2013
Establishment of Camden RAD, LLC, a company devoted to stem cell research and development.
Q4 2017
Camden RAD, LLC is rebranded as Stem Cell Innovations, and a new company is established, based on blockchain technology.

Advanced research begins to determine market and development opportunities.
Q1 2018
Attended Token 2049 conference in Hong Kong.

Attended Stem Cell Summit at the University of California in Los Angeles (UCLA).

Attended CBC conference in San Francisco, CA.
Q2 2018
Attended ICO20 Summit in Santa Monica, CA.

Integration of smart contract technology is established.

Company headquarters incorporated in Gibraltar, GB.

Strategic efforts toward development begins.

Interviews with potential medical participants take place.
Q3 2018
Whitelist is scheduled to go live.

Token Sale starts.
Q4 2018
Token Sale ends and min max caps are assessed.

Distribution of Tokens to participants through ERC20 will commence.
Q1 2019
SCI will begin final testing and reporting based on blockchain technology being used.

Creation of a non-identical patient identification factor on Passive Blockchain Node will be initialized.

Demo testing for SCI Application v 1.0 will begin.
Q2 2019
Release of the SCI Application v1.1

Enrollment begins for doctors, patients, and stem cell laboratories in the United States
Q3 2019
Release of Market Surveillance strategy for further growth

Release SCI Application v2.0

Enrollment begins for professionals, patients, and stem cell laboratories in Middle East and across North Africa.

Announcement of first SCI Lab location and franchise expansion plan.
Q4 2019
Announcement of clinical development and research strategy in the stem cell field.

Public announcement regarding SCI achievements to date.

First ever online synthetic stem cell purchase through the SCI Application. Release SCI Application v3.0, fully functional platform for professionals and patients.
Q1 2020
Stem Cell Lab Evaluation report per first year of operation and development.

Release SCI earnings and financials report.

Release results of SCI's stem cell research and development to date.
Q2 2020
Expansion of SCI stem cell labs and clinics in China, Japan, South Korea, and India.

Begin charging membership fees (payable in Stem Cell Innovations tokens) for professional-facing portion of SCI application.
Q3 2020
Begin second phase of SCI stem cell research and development.

Release SCI Application v3.5, including professional-facing component to help practitioners become more involved in the stem cell research space and contribute to the network.
Q4 2020
Expansion and acquisition of SCI stem cell labs and clinics in Europe.
Q1 2021
Release SCI earnings and financials report for second year operation and development.

Release public update on SCI stem cell research and development.

Stem Cell Lab Evaluation report for second year.
Q2 2021
Release SCI Application v4.0 including:

A new platform for medical students, universities, and hospitals to engage with the SCI Application.

Fully Functional EMR Worldwide Enforcing HIPPA and expanding of synthetic stem cell delivery to Latin America.
Screenshots taken 13 Sep 2018
Moe Galal
Chief Executive Officer / Founder
Ben Barel
Chief Operations Officer / Co-Founder
Ali Alrashidi
Chief Technology Officer / Co-Founder
Matt Galal
Chief of Staff / Co-Founder
Kobi Barel
Operations Engineer / Co-Founder
John Glavinovich, M.D.
Medical Director
Philip Glukhovsky, D.C.
Health Informatics Manager
Roger Williams
VP of Marketing
Liz Curlett
VP, PR & Corporate Communications
Candice Kouchache
Business Development
Ahmed Elsantawi
VP of International Human Resources
David Marmon
Web Designer
Heather Deveaux
Copywriter
Everlecia Taylor
Creative Writer
Marina Evglevskaya
Administrative Manager
Rakel Apodaca
Product Manager
Michelle Chavon
Marketing

Advisors (7)

Boyan Josic
Marc X. Ellul
Roger Shortz, M.D.
Greg Maddex, D.O
Pantea Nakieen, M.D.
Shahab Sajadi
Igor Soshkin
HEIGHT - 0px
WIDTH - 0px
PUT THIS CODE TO YOUR WEBSITE
ICO List
Other Interesting ICOs
Active
Cryptoprofile
Empowering a blockchain revolution towards a safer and more secure ICO ecosystem. CryptoProfile (CP) has initiated a transformative idea that will revolutionize cryptocurrency airdrops and prove highly beneficial for those holding CP tokens.
Upcoming
DeepCloud
DeepCloud AI is building an AI-driven decentralized cloud computing platform for running decentralized applications — IoT and Web 3.0 dApps. We will provide a spot market for computing and storage resources for enterprise-level users and individuals, for the purpose of sharing their excess capacity on our decentralized cloud, and with our AI matching engine. Applications will execute in a secure sandbox on the peer-to-peer resources, and all transactions are managed on the blockchain via smart contracts.
Upcoming
ECTA
ECTA (Efficient Collaboration Team Autonomous) is the first blockchain-based trust protocol for global employability of developers. The concept, empowered by the proven AI tools, aims to solve the inefficiencies related to the time loss, verification of online profiles, talents discovery (especially in the low-middle income countries) and safe way to conduct business (payment solution with the power of smart contracts). While working on ECTA platform, besides collecting their earnings in ECTA tokens (ERC20) developers are having a unique possibility to earn (mine) ECTA non-fungible tokens (ERC721) as a reward for every task completed - which serve as proof of their skills and increase their reputation. AI component of the platform helps companies worldwide discover and employ these developers in a safe and productive way for both sides.
Upcoming
DINNGO
The first exchange to enable simple two step verification with mobile device and cold wallet. Dinngo is revolutionising the way we trade digital currencies. Our cold wallet integrates seamlessly with the Dinngo exchange, providing the secure, fast and convenient asset trading service the market needs.
Upcoming
AITrading
AITrading is a revolutionary trading ecosystem, which simplifies experience both for experienced traders as well as for newcomers. It gives tens millions traders the ability to live normal life while AI works for them. AITrading combines AI and Blockchain technologies with trading community capabilities on a single platform.
Active
Geon
Geon Network is a service that allows you to create virtual objects(Geons) located anywhere in the world. You can deposit funds (Geon Coins) in Geons, which can be withdrawn by anyone nearby. In order to withdraw, users need to complete the tasks defined by the Geon creator.